Hongene Biotech Corporation has announced its support for SiranBio’s SA1211 programme, a dual-target siRNA therapeutic candidate being developed for chronic hepatitis B. The collaboration highlights Hongene’s growing capabilities in providing integrated development and manufacturing solutions for structurally complex oligonucleotide therapeutics.

Under the programme, Hongene delivered vertically integrated Contract Development and Manufacturing Organization (CDMO) services covering raw material production, process and analytical development, current Good Manufacturing Practice (cGMP) drug substance and drug product manufacturing, as well as Chemistry, Manufacturing and Controls (CMC) and regulatory support.

The collaboration reflects the increasing complexity of next-generation siRNA therapeutics and the growing need for advanced expertise in synthesis, impurity control, scale-up and clinical-stage manufacturing. SA1211 was manufactured using traditional solid-phase oligonucleotide synthesis, demonstrating Hongene’s technical depth in handling complex RNA-based molecules.

Commenting on the development, Dr. David Butler, Chief Technology Officer at Hongene, said that programmes such as SA1211 illustrate the evolving direction of the siRNA therapeutics space, where increasing molecular complexity requires stronger development and manufacturing capabilities. He added that Hongene aims to provide customers with the technical expertise and flexibility needed to advance these programmes with confidence.

Dr. Butler also noted that while the SA1211 programme utilised conventional synthesis methods, the company is already applying its chemoenzymatic ligation platform to other complex dual-targeting siRNA programmes under development. According to him, this approach could offer a scalable, modular and high-purity manufacturing route for future next-generation constructs.

The programme further reinforces Hongene’s position as a specialised CDMO partner for innovative oligonucleotide therapeutics, particularly in areas where manufacturing precision and execution are critical for programme success.

Founded in 1998 and incorporated in Singapore, Hongene Biotech Corporation is a global RNA technology provider focused on the design, synthesis and large-scale manufacturing of high-purity nucleic acid raw materials and therapeutics for biotechnology and pharmaceutical companies worldwide.